Excessive weight loss on Zepbound linked to more hospitalizations
Adverse events linked to weight loss occurred at 39.4 per 100 patient-years in people losing 30% or more, compared with 14.4 in those losing 5% to 15%.
3,348 participants, 1 year
Limit: Documentation differences and variation in doctor note-taking may have affected the results
Edited by Boris Djordjevic · AgingResearch.News
In an observational study released as a preprint, researchers analyzed electronic health records of patients who started taking the obesity medication Zepbound (tirzepatide). They compared 837 patients who lost at least 30% of their body weight in their first year with 3,348 matched patients who experienced moderate weight loss of 5% to 15%.
Problems that doctors attributed to weight loss affected 35.1% of patients with excessive weight loss compared with 14.3% in the moderate group. These issues included falls, muscle loss, weakness, fainting, and low blood pressure. In addition, 25.7% of patients with excessive weight loss were hospitalized, compared with 15.7% of those with moderate loss, and 5.3% were admitted to intensive care, compared with 2.3%. Blood tests also showed higher rates of anemia and low levels of sodium, potassium, and calcium.
Why it matters
Muscle loss, falls, and heart failure are major health concerns that become more common with age. The findings support moving toward individualized weight-loss goals and suggest that greater weight reduction may not always translate into better health outcomes.
Caveats
Because this observational study relied on health records, unmeasured health differences between patients and variation in how doctors took notes may have influenced the results. The research was released as a preprint and used a computer language model to extract adverse events from clinic notes rather than tracking patients in a controlled trial.
Caloric restriction is part of Bryan Johnson's Blueprint
The paper
Preprints.org, Oct 21, 2026, Open access, Preprint, not peer-reviewed
